| SHORT COMMUNICATION |
|
| Year : 2018 | Volume
: 63
| Issue : 1 | Page : 62-65 |
|
|
Adverse reactions due to the bacillus Calmette-Guerin vaccine: Twenty Tunisian cases
Khadija Sellami1, Meriem Amouri1, Sana Kmiha2, Emna Bahloul1, Hajer Aloulou2, Lamia Sfaihi2, R Guirat2, Madiha Mseddi1, T Kamoun2, Mongia Hachicha2, Hamida Turki1
1 Department of Dermatology, Hedi Chaker Hospital, Sfax, Tunisia
2 Department of Paediatrics, Hedi Chaker Hospital, Sfax, Tunisia
Correspondence Address:
Dr. Khadija Sellami
Department of Dermatology, Hedi Chaker Hospital, Sfax
Tunisia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijd.IJD_327_17
|
|
|
Background: Bacillus Calmette-Guérin (BCG) vaccine is a widely used vaccine. Management of local BCG complications differs between clinicians, and the optimal approach remains unclear. Aims: We aim to describe the epidemiological, clinical and therapeutic aspects of the BCG vaccine side effects in Sfax. Patients and Methods: This was a retrospective study of all the cases of BCG vaccine adverse reactions recorded in the Dermatology and Paediatrics Departments of Hedi Chaker University Hospital of Sfax over a period of 10 years (2005–2015). Results: Twenty cases of BCG adverse reactions were notified during the study period. Actually, 80% of the patients presented local adverse reactions. The outcome was good in all the followed patients. The rate of disseminated BCG disease was 20%. Biological tests of immunity showed a primary immunodeficiency in three cases, whereas the outcome was fatal in two cases. Conclusion: BCG vaccine adverse reactions range from mild to severe. However, the management of benign local reactions remains unclear. Disseminated BCG disease must alert clinicians to the possibility of a primary immunodeficiency.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
